Analyst Yanan Zhu of Wells Fargo maintained a Hold rating on Sangamo Biosciences (SGMO – Research Report), retaining the price target of ...

During post-market hours on December 30, 2024, Sangamo announced that Pfizer, with whom the Company was co-developing hemophilia A gene therapy candidate giroctocogene fitelparvovec, would be ...

RICHMOND, Calif., December 30, 2024--SANGAMO THERAPEUTICS TO REGAIN FULL RIGHTS TO HEMOPHILIA A GENE THERAPY PROGRAM FOLLOWING PFIZER’S DECISION TO CEASE DEVELOPMENT Astellas Pharma Inc. (TSE ...

Sangamo chief executive Sandy Macrae has said the company is "surprised and extremely disappointed" by Pfizer's decision to hand back rights to its experimental gene therapy for haemophilia A ...

Truist Securities adjusted its outlook for Sangamo BioSciences, reducing the price target on the company's shares to $5 from ...

Sangamo CEO Sandy Macrae told us how his company ... Fabry disease and hemophilia A (in partnership with Pfizer). The next ‘easiest’ area for the company to take on with its existing ...

Pfizer Inc. (NYSE:PFE) will increase its dividend from last year's comparable payment on the 7th of March to $0.43. This will take the annual payment to 6.5% of the stock price, which is above ...

Get Our Latest Stock Analysis on PFE Pfizer Trading Down 0.7 % Shares of PFE stock opened at $26.30 on Monday. The stock has a market cap of $149.06 billion, a P/E ratio of 35.55, a P/E/G ratio of ...

Pfizer Trading Down 0.7 % Shares of PFE opened at $26.30 on Monday. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. Pfizer Inc. has a 1-year low ...